<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="195">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04795414</url>
  </required_header>
  <id_info>
    <org_study_id>RJHKY2021-12</org_study_id>
    <nct_id>NCT04795414</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of an Inactivated Vaccine Against COVID-19 in Medical Workers</brief_title>
  <official_title>Safety and Immunogenicity of an Inactivated Vaccine Against COVID-19 in Medical Workers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      With the unprecedented morbidity of the COVID-19 pandemic, the vaccine effectiveness needs to&#xD;
      be assessed across diverse populations. The purpose of this study is to evaluate the safety&#xD;
      and immunogenicity of an inactivated SARS-CoV-2 vaccine in medical workers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1370 participants who were negative for serum-specific antibodies against SARS-CoV-2 at the&#xD;
      time of screening were enrolled and were receive a two-dose schedule, 21 days apart, with 4&#xD;
      μg BBIBP-CorV inactivated SARS-CoV-2 vaccine. The primary safety outcome includes solicited&#xD;
      local and systemic reactions prompted by and recorded in an electronic diary within 7 days&#xD;
      post each injection, unsolicited adverse events and serious adverse events assessed from the&#xD;
      receipt of each dose, and clinical laboratory abnormalities from dose 1 through 1month after&#xD;
      dose 2. Laboratory tests included measurement of alanine aminotransferase, aspartate&#xD;
      aminotransferase, serum total bilirubin, serum albumin, creatinine, blood urea nitrogen, and&#xD;
      blood routine examination. Immunogenicity was assessed as the serum anti-SARS-CoV-2 specific&#xD;
      antibody responses and neutralizing activity at 4 weeks after the second vaccination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants reporting local reactions</measure>
    <time_frame>within 7days post each vaccination</time_frame>
    <description>Pain at the injection site, swelling, itch, and redness</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting systemic events</measure>
    <time_frame>within 7days post each vaccination</time_frame>
    <description>Fever, headache, fatigue, nausea, vomiting, diarrhea, constipation, myalgia, arthralgia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting adverse events</measure>
    <time_frame>From Dose 1 through 1 month after Dose 2</time_frame>
    <description>verified by investigators</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting serious adverse events</measure>
    <time_frame>From Dose 1 through 1 month after Dose 2</time_frame>
    <description>verified by investigators</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum anti-SARS-CoV-2 speicfic antibody and neutralizing antibody titres</measure>
    <time_frame>at 1 month after dose 2</time_frame>
    <description>determination of anti-SARS-CoV-2 speicfic antibody and SARS-CoV-2 neutralizing antibody levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum anti-SARS-CoV-2 speicfic antibody and neutralizing antibody titres</measure>
    <time_frame>at 6 months after dose 2</time_frame>
    <description>determination of anti-SARS-CoV-2 speicfic antibody and SARS-CoV-2 neutralizing antibody levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum anti-SARS-CoV-2 speicfic antibody and neutralizing antibody titres</measure>
    <time_frame>at 12 months after dose 2</time_frame>
    <description>determination of anti-SARS-CoV-2 speicfic antibody and SARS-CoV-2 neutralizing antibody levels</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1370</enrollment>
  <condition>SARS-CoV-2 Infection</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Vaccination Group</arm_group_label>
    <description>Participants vaccinated with inactivated SARS-CoV-2 vaccine are studied for safety and antibody response.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SARS-CoV-2 Vaccine(Vero Cell), Inactivated</intervention_name>
    <description>The subjects of Vaccination Group will receive two doses, 21 days apart of inactivated SARS-CoV-2 vaccine (4 μg of BBIBP-CorV)</description>
    <arm_group_label>Vaccination Group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample, including plasma, serum and blood cell&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Medical workers in Ruijin Hospital who are willing to receive two dose of SARS-CoV-2&#xD;
        inactivated vaccine via intramuscular injection in the arm&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent according to ICH/GCP regulations prior to any trial specific&#xD;
             procedures.&#xD;
&#xD;
          -  Male or female aged 18-59 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  NA&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erzhen Chen</last_name>
    <role>Study Director</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xinxin Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ZhiTao Yang</last_name>
    <phone>+8613611965436</phone>
    <email>yangzhitao@hotmail.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaoqi Yu</last_name>
    <phone>+8613817390935</phone>
    <email>yuxiaoqi_03@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ruijin Hospital affiliated to Shanghai JiaoTong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ZhiTao YANG</last_name>
      <phone>+8613611965436</phone>
      <email>yangzhitao@hotmail.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Covid19</keyword>
  <keyword>Inactivated vaccine</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

